Patients in the Veritac-2 study were randomized to receive a standard estrogen blocker called fulvestrant, or Arvinas' ...

Investors face some tough options for the new year, as the S&P 500 pulls back mildly while the growth-, tech- and Mag ...

Analysts at Morgan Stanley say Microsoft (NASDAQ: MSFT) is in a "pole position" to capitalize on growing demand for ...

But a pair of treatments that launched in 2019 are already offsetting Humira's losses. Combined sales of Skyrizi, a psoriasis ...

TransDigm Group benefits from robust air travel demand and supply chain disruptions. Read why I downgrade TDG stock from buy ...

Read here for an analysis of Inter's strong financial position, growth potential, and valuation vs. peers, with potential for ...

Jon Smith talks through the scale of Nvidia stock growth over the past year but questions if further gains are going to be ...

Biote: Revolutionizing Hormone Optimization Biote (NYSE: BTMD) represents an innovative play in the growing hormone ...

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, January 21st: nCino, ...

South Korea will tighten regulations on stock market listings to improve the quality and competitiveness, the financial ...

ETF has done well in the past decade as it became one of the biggest dividend and sleep-well-at-night (SWAN) funds. It has ...

Corning Incorporated (NYSE:GLW), a leading innovator in materials science with a market capitalization of $42.73 billion, has ...